Navigation Links
Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
Date:11/6/2010

ATLANTA, Nov. 6, 2010 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced that data from two clinical studies of its ALD518 investigational antibody therapeutic will be presented at the Annual Meeting of the American College of Rheumatology in Atlanta.

"We continue to be encouraged about the clinical data from the Phase 2a study of the IV formulation of ALD518, and, for the first time, from our Phase 1 study of the subcutaneous formulation of ALD518," said Randall Schatzman, president and chief executive officer of Alder Biopharmaceuticals.

Data from the Phase 2a clinical study of ALD518 in rheumatoid arthritis patients will be delivered by Philip Mease, M.D., investigator at the Swedish Hospital Clinical Research Division in Seattle, in a presentation titled "ALD518 (BMS945429), a High Affinity Monoclonal Antibody Directed Against Interleukin-6, Reduces Disease Activity and Achieves Remission in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate." The presentation will be delivered at 4:30 p.m. EST on Wednesday Nov. 10, in the abstract session titled "Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Novel Compounds III."

Data from a Phase 1 clinical study of a subcutaneous formulation of ALD518 will be presented in a poster titled "Safety, Pharmacokinetics and Pharmacodynamics of ALD518 (BMS-945429), a High-Affinity Monoclonal Antibody Directed Against Interleukin-6 (IL-6) Administered by Subcutaneous Injection: A Phase I Trial." The poster, 1124, will be presented by Sepehr Shakib, M.D., director of pharmacology at Royal Adelaide Hospital in Adelaide, Australia, in poster session B.

In addition, data evaluating health-related quality of life of patients in a Phase 2a study of ALD518 will be presented in a poster titled "ALD518 (BMS945429), a High-Affinity Anti-Interleukin-6 Monoclonal Antibody, Provides Improvements in Health-Related Quality of Life (HRQoL) in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate." The poster, 1096, will be presented in poster session B by Vibeke Strand, M.D., clinical professor of medicine at Stanford University in Palo Alto, Calif.

About Rheumatoid ArthritisRheumatoid arthritis (RA) is a systemic, chronic autoimmune disease characterized by inflammation in the lining of joints (or synovium), causing joint damage with chronic pain, stiffness, swelling and fatigue. RA causes limited range of motion and decreased function as a result of affected joints losing their shape and alignment.

RA affects about 1 percent of the world's population, including more than 1 million people in the United States. The condition is more common in women than in men, who account for 75 percent of patients diagnosed with RA.

About Alder BiopharmaceuticalsAlder Biopharmaceuticals Inc. uniquely identifies, develops and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas. Alder's management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics and enabling partners through the out-licensing of its technologies. ALD518 is an investigational monoclonal antibody to the pro-inflammatory cytokine IL-6 that is being developed by Bristol-Myers Squibb for autoimmune indications. In addition to Bristol-Myers Squibb, partners include Merck and Genmab. For more information, visit www.alderbio.com.Media Contact: Ian Stone or David SchullRusso PartnersTel: +1 619-528-2220ian.stone@russopartnersllc.comdavid.schull@russopartnersllc.com
'/>"/>

SOURCE Alder Biopharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
2. Encision Enters Into Sales Representation Agreement With Caldera Medical
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
4. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
5. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
6. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
7. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
8. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
9. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
10. Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients
11. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
Breaking Biology News(10 mins):